BlackRock Units Together Hold 5.3% Of Shattuck Labs, A Passive Stake Worth Watching

BlackRock reported 5,339,458 shares of the Crohn's-focused biotech, with sole voting power over 5,221,737 of them.

Share
BlackRock Units Together Hold 5.3% Of Shattuck Labs, A Passive Stake Worth Watching

BlackRock says several of its business units together hold 5,339,458 shares of Shattuck Labs, or 5.3% of the common stock, according to a passive ownership filing (a Schedule 13G) made Tuesday. Shattuck, a clinical-stage biotech, closed at $5.77 on Tuesday, giving it a market value of $556 million.

Votes and the reporting units

BlackRock reported sole voting power over 5,221,737 of the shares and no shared voting power. The filing sets the event date at September 30, 2026 and classes BlackRock as a parent holding company filing on behalf of its units.

An exhibit names the units: BlackRock Advisors, BlackRock Fund Advisors, BlackRock Institutional Trust Company, BlackRock Financial Management and BlackRock Investment Management.

The filing says various persons have the right to receive dividends or sale proceeds from the stock, and that no one person's interest exceeds 5% of the outstanding shares.

A passive holder, by certification

BlackRock certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Shattuck.

A Crohn's drug in early testing

Shattuck, based in Austin, Texas, develops antibodies that block a protein called Death Receptor 3 to treat inflammatory and immune-mediated diseases. Its lead candidate, SL-325, is in an early-stage trial in healthy volunteers, and the company plans a mid-stage trial in Crohn's disease patients to begin in the third quarter of 2026, it said in its annual report.

The company has no approved products and relies on a single contract manufacturer, Kemwell Biopharma, for the bulk drug substance of SL-325.

The position sits just over the 5% line that triggers a 13G filing, with the stock at $5.77 at Tuesday's close.

Sources

More on Shattuck Labs

All Shattuck Labs (STTK) coverage →